MaxCyte Inc.

11/14/2019 | Press release | Archived content

Presentation at Jefferies Healthcare Conference

RNS Reach Story
Go to market news section
MaxCyte, Inc. - MXCT

Presentation at Jefferies Healthcare Conference

Released 07:00 14-Nov-2019



RNS Number : 3429T
MaxCyte, Inc.
14 November 2019

MaxCyte to Present at 2019 Jefferies London Healthcare Conference

Gaithersburg, Maryland - 14November 2019- MaxCyte (LSE: MXCT, MXCS),the global cell-based therapies and life sciences company, announces that President and Chief Executive Officer Doug Doerfler will presentat the 2019 Jefferies London Healthcare Conference, to be held 20-21 November at the Waldorf Hilton Hotel.

The presentation will take place at 3:20 p.m. GMT on Thursday, 21 November, and will focus on MaxCyte's position at the forefront of the development of next generation cell-based medicines through its Life Sciences business and proprietary CARMA™ platform.

The presentation will be made available after the conference on the Investor sectionof MaxCyte's website.

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 80 partnered programme licenses in cell therapy with more than 45 licensed for clinical use, including six announced commercial licenses with aggregate potential milestones of more than $450m. With its robust delivery technology platform, MaxCyte helps its partners to unlock the full potential of their products. For more information, visit www.maxcyte.com.

For further information, please contact:

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Ron Holtz, Chief Financial Officer

+1 301 944 1660

Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

Sukaina Virji

+44 (0)203 709 5700

[email protected]



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
NRACKNDKFBDDNDD
Close
London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.
©2014London Stock Exchange plc. All rights reserved



Presentation at Jefferies Healthcare Conference - RNS